Morgan Stanley has upgraded PTC Therapeutics (NASDAQ:PTCT), while downgrading Immuneering (NASDAQ:IMRX) and Amicus Therapeutics (NASDAQ:FOLD). The investment bank raised its rating on PTC (NASDAQ:PTCT ...

Qure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reaffirmed by Guggenheim in a report released on ...

uniQure (NASDAQ:QURE – Get Free Report) shares saw strong trading volume on Wednesday after The Goldman Sachs Group raised ...

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

Leerink raised the firm’s price target on uniQure (QURE) to $44 from $26 and keeps an Outperform rating on the shares. The firm notes the ...

Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

Qure (NASDAQ:QURE – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday. Other research analysts have also ...

Shares of Needham, Mass.-based Candel Therapeutics Inc. (NASDAQ:CADL) were trading at $11.16, up $6.55, or 142%, on results from a multicenter phase III trial with CAN-2409 viral immunotherapy in ...

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...

The U.S. FDA has greenlit the first steps of Uniqure NV’s accelerated approval pathway for gene therapy AMT-130 to treat Huntington’s disease. The agency said data from the ongoing phase I/II studies ...

European shares closed lower today. The eurozone's STOXX 600 fell 0.52%, Germany's DAX fell 0.08% and France's CAC 40 fell ...